Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
申请人:Pfizer Products Inc.
公开号:EP1081143A1
公开(公告)日:2001-03-07
A novel process intermediate, tetrahydro-4-[3-(4-fluorophenyl)thio]phenyl-2H-pyran-4-carboxamide, of the formula:
is described, as well as its use in a process of preparing 5-lipoxygenase inhibitors of the formula:
which comprises establishing a reaction mixture consisting of:
- and - an electron deficient monocyclic or benzo-fused bicyclic N-heterocycle containing two nitrogen atoms of the formula:
in an aprotic solvent; in the presence of a carbonate of the formula: (M)2-CO3, where M is an alkali metal, Group 1/Ia element, selected from the group consisting of lithium, Li; sodium,Na; potassium, K; rubidium, Rb; and cesium, Cs; followed by heating of said reaction mixture under a nitrogen atmosphere; whereby there is produced the desired compound of the above-recited formula.
本发明描述了一种新型工艺中间体--式中的四氢-4-[3-(4-氟苯基)硫]苯基-2H-吡喃-4-甲酰胺:
描述了其在制备式 5-脂氧合酶抑制剂工艺中的用途:
的反应混合物,其中包括
- 式中含有两个氮原子的缺电子单环或苯并融合双环 N-杂环; - 式中含有两个氮原子的缺电子单环或苯并融合双环 N-杂环; - 式中含有两个氮原子的缺电子单环或苯并融合双环 N-杂环:
在壬烷溶剂中,在式:(M)2-CO3,其中 M 是碱金属,第 1/Ia 族元素,选自由锂 Li、钠 Na、钾 K、铷 Rb 和铯 Cs 组成的组。